Atai Life Sciences NV Form 4 insider transactions

Glenn Frank Short, Chief Scientific Officer of ATAI Life Sciences N.V., was granted stock options for 757,915 common shares on March 3, 2025.

Kevin James Craig, Chief Medical Officer of ATAI Life Sciences N.V., was granted stock options for 757,915 common shares on March 3, 2025.

Anne Nagengast Johnson, CFO of ATAI Life Sciences N.V., reports the acquisition of stock options.

Apeiron Investment Group significantly increased its holdings in ATAI Life Sciences through a recent purchase of shares.

ATAI Life Sciences N.V. reports that CEO Srinivas Rao was granted 2,340,000 stock options on January 7, 2025, with vesting starting in 2026.

Chief Operating Officer Gerd Kochendoerfer of ATAI Life Sciences N.V. was granted 1,450,000 stock options on January 2, 2025, vesting over a three-year period.

Christian Angermayer, a director and 10% owner of ATAI Life Sciences N.V., extended the expiration dates of certain pre-IPO stock options to align with the company's 2021 Incentive Award Plan.

Anne Nagengast Johnson, CFO of ATAI Life Sciences N.V., reports adjustments to the expiration dates of her pre-IPO stock options to align with the company's 2021 Incentive Award Plan.

Srinivas Rao, an officer of ATAI Life Sciences N.V., reports extending the expiration dates of previously awarded pre-IPO stock options to align with the company's 2021 Incentive Award Plan.

Florian Brand, Co-CEO of ATAI Life Sciences, reports extending the expiration dates of previously awarded pre-IPO stock options to align with the company's 2021 Incentive Award Plan.

ATAI Life Sciences N.V. reports the sale of 2,660,000 Ordinary Shares of COMPASS Pathways plc at $6.05 per share on September 26, 2024.

Michael Auerbach, a director of ATAI Life Sciences N.V., acquired stock options for 103,000 common shares on June 13, 2024.

Christian Angermayer, a director and 10% owner of ATAI Life Sciences N.V., acquired 103,000 stock options on June 13, 2024.

Andrea Heslin Smiley, a director at ATAI Life Sciences N.V., acquired stock options for 103,000 common shares on June 13, 2024.

Director Scott Braunstein acquired 206,000 stock options in Atai Life Sciences N.V. on June 13, 2024.

Laurent Fischer, a director at ATAI Life Sciences N.V., acquired stock options for 206,000 common shares on June 13, 2024.

Director Amir H. Kalali acquired 103,000 stock options in Atai Life Sciences N.V. on June 13, 2024.

Sabrina Martucci Johnson, a director of ATAI Life Sciences N.V., acquired 103,000 stock options on June 13, 2024.

Florian Brand, Co-Founder & CEO of ATAI Life Sciences N.V., sold 151,303 common shares to cover tax liabilities arising from the vesting of restricted stock units.

ATAI Life Sciences N.V. reports the acquisition of convertible notes in IntelGenx Technologies Corp. through a term loan provided by its subsidiary, ATAI AG.

Apeiron Investment Group Ltd., a significant shareholder in ATAI Life Sciences N.V., reports changes in beneficial ownership related to convertible notes.

Anne Nagengast Johnson, CFO of ATAI Life Sciences N.V., sold 27,410 common shares on April 2, 2024, at a price of $1.85 per share to cover tax liabilities related to vesting restricted stock units.

Srinivas Rao, Chief Scientific Officer of ATAI Life Sciences, sold 61,640 common shares on April 2, 2024, to cover tax liabilities arising from the vesting of restricted stock units.

Sahil Kirpekar, Chief Business Officer of ATAI Life Sciences N.V., sold 35,801 common shares on April 2, 2024, to cover tax liabilities arising from the vesting of restricted stock units.

Anne Nagengast Johnson, CFO of ATAI Life Sciences N.V., reports the acquisition of stock options and vesting of restricted stock units (RSUs).

Sahil Kirpekar, Chief Business Officer of ATAI Life Sciences N.V., reports acquisition of stock options and settlement of restricted stock units.

Srinivas Rao, Co-Founder & Chief Scientific Officer of ATAI Life Sciences N.V., reports acquisition of shares and stock options.

Florian Brand, CEO of ATAI Life Sciences, exercised 350,000 restricted stock units into common shares on March 14, 2024.

ATAI Life Sciences N.V. reports transactions involving convertible notes, warrants, and common stock of IntelGenx Technologies Corp., indicating changes in beneficial ownership.